KEVEYIS Drug Patent Profile
✉ Email this page to a colleague
When do Keveyis patents expire, and what generic alternatives are available?
Keveyis is a drug marketed by Xeris and is included in one NDA.
The generic ingredient in KEVEYIS is dichlorphenamide. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the dichlorphenamide profile page.
Summary for KEVEYIS
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 92 |
| Patent Applications: | 3,842 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for KEVEYIS |
| What excipients (inactive ingredients) are in KEVEYIS? | KEVEYIS excipients list |
| DailyMed Link: | KEVEYIS at DailyMed |
DrugPatentWatch® Estimated Generic Entry Opportunity Date for KEVEYIS
Generic Entry Date for KEVEYIS*:
Constraining patent/regulatory exclusivity:
TREATMENT OF PRIMARY HYPERKALEMIC PERIODIC PARALYSIS, PRIMARY HYPOKALEMIC PERIOD PARALYSIS, AND RELATED VARIANTS NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for KEVEYIS
| Drug Class | Carbonic Anhydrase Inhibitor |
| Mechanism of Action | Carbonic Anhydrase Inhibitors |
US Patents and Regulatory Information for KEVEYIS
KEVEYIS is protected by zero US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of KEVEYIS is See Plans and Pricing.
This potential generic entry date is based on TREATMENT OF PRIMARY HYPERKALEMIC PERIODIC PARALYSIS, PRIMARY HYPOKALEMIC PERIOD PARALYSIS, AND RELATED VARIANTS.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
FDA Regulatory Exclusivity protecting KEVEYIS
TREATMENT OF PRIMARY HYPERKALEMIC PERIODIC PARALYSIS, PRIMARY HYPOKALEMIC PERIOD PARALYSIS, AND RELATED VARIANTS
Exclusivity Expiration: See Plans and Pricing
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xeris | KEVEYIS | dichlorphenamide | TABLET;ORAL | 011366-002 | Aug 7, 2015 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
